#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians should be aware that current evidence does not support recommending cannabis as a treatment for depression, anxiety, or PTSD, which can help them counsel patients seeking cannabis for these common mental health conditions. Patients with these conditions need evidence-based treatments such as psychotherapy or FDA-approved medications rather than unproven alternatives that may delay effective care. This evidence gap is particularly important given the increasing availability of cannabis products and patient interest in using them for mental health purposes.
A systematic review examining medicinal cannabis for depression, anxiety, and post-traumatic stress disorder found insufficient evidence to support its efficacy for these common psychiatric conditions. While cannabis has been increasingly sought by patients with mental health disorders, the available clinical data does not demonstrate meaningful therapeutic benefit comparable to established pharmacological and psychological treatments. The review highlights a significant gap between patient interest and clinical evidence, with most studies showing either no significant improvement or results confounded by concurrent use of other psychiatric medications. This evidence gap is particularly important given that some patients may delay or avoid evidence-based treatments like antidepressants or psychotherapy in favor of cannabis use. Clinicians should counsel patients that current evidence does not support cannabis as a primary or adjunctive treatment for depression, anxiety, or PTSD, and should continue recommending established first-line therapies for these conditions. When patients inquire about cannabis for mental health symptoms, physicians should present this lack of supporting evidence while discussing the proven effectiveness of conventional psychiatric medications and psychological interventions.
“The absence of evidence for cannabis in depression, anxiety, and PTSD should inform our prescribing, not discourage rigorous investigation, because we’re seeing patients report symptomatic relief in practice while our clinical trials lag behind. What concerns me more than the negative evidence is that we’re treating these conditions with FDA-approved medications that carry their own significant side effect burdens, yet we’re not willing to study cannabis with the same methodological rigor we’d apply to a new pharmaceutical compound.”
🧠 Current evidence does not support medicinal cannabis as a first-line or standalone treatment for depression, anxiety, or post-traumatic stress disorder, despite growing patient interest and jurisdictional legalization. While the analogy to methadone’s role in opioid use disorder is intriguing, the neurobiological mechanisms and evidence base differ substantially, and most rigorous clinical trials have failed to demonstrate efficacy for these common psychiatric conditions. Clinicians should remain cautious about endorsing cannabis for mood or anxiety disorders given the potential for symptom exacerbation, cognitive effects, and the risk of cannabis use disorder itself, particularly in vulnerable populations. However, this does not preclude individualized discussion with patients already using cannabis or exploring emerging cannabinoid research, provided that evidence-based first-line treatments like psychotherapy and pharmacotherapy remain the foundation of care. A practical approach is to maintain clear communication about the current lack of evidence, document patient
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: